Furthermore, its success in the Canakinumab Anti-inflammatory Thrombosis Outcome Study trial revealed that IL-1β blockade also lowers cardiovascular event rates in patients with elevated inflammatory markers, highlighting the role of IL-1β in atherogenesis and systemic inflammation [407–409]. The gene discussed is IL1B; the disease is deep vein thrombosis.